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Introduction
Myotonic Dystrophy type 1 (DM1, OMIM #160900) is an autosomal dominant disease caused by the expansion of a CTG trinucleotide repeat in the 3' untranslated region (UTR) of the dystrophia myotonica protein kinase (DMPK) gene. Characteristic symptoms include myotonia, progressive muscle wasting, and cardiac conduction defects, among other systemic manifestations. The molecular mechanisms underlying DM1 pathogenesis are complex and affect a large number of cellular processes 1 . However, most data suggest that the main triggering event is a toxic gain-of-function of the expanded CUG RNA. CUG repeat expansions form double-stranded hairpins that are retained as inclusions within the nucleus. These hairpins recruit a number of transcription and splicing factors, including Muscleblindlike 1 (MBNL1) [2] [3] [4] [5] [6] . Sequestration of MBNL1 originates a loss-of-function, which plays a key role in the development of DM1 symptoms. Mbnl1 knockout mice reproduced typical features of DM1, and overexpression of Mbnl1 in a mouse model that expressed CTG repeats reversed these phenotypes 7, 8 . CTG-repeat expression in mice caused misregulation of at least 156 alternative splicing events. Of these, 128 also occurred in Mbnl1 knockout animals [9] [10] [11] [12] . The splicing factor CUG-Binding Protein 1 (CUGBP1) is another key component in the development of DM1 phenotypes. CUGBP1 antagonizes MBNL1 activity in the regulated use of alternative exons in a number of transcripts, and is abnormally upregulated in patients with DM1, further contributing to splicing misregulation [13] [14] [15] .
Mahadevan et al. provided the first in vivo proof-of-principle for a therapeutic strategy based on ablating toxic RNA molecules in DM1 16 . They demonstrated that expanded CTG-induced effects could be reverted if CTGrepeat transgene expression was interrupted in a DM1 mouse model. Several other groups developed synthetic molecules and (CAG)n oligonucleotides that disrupted MBNL1 interaction with expanded CUG repeats [17] [18] [19] [20] [21] [22] . However, those approaches may not address all the pathological consequences of expanded CUG RNAs. Moreover, unspecific MBNL1-RNA binding inhibition could affect other normal MBNL1-dependent splicing events. Therefore, it would be desirable to identify molecules that target toxic repeats without interfering with cellular, non-pathological MBNL1-RNA interactions.
Results
In vivo screening of a combinatorial peptide library in Drosophila identified a hexapeptide that suppressed CUG toxicity
The targeted expression of 480 interrupted CTG repeats, UASi (CTG) 480 , to the Drosophila brain structure the Mushroom Bodies (MB) with the X-linked 103Y-Gal4 driver (103Y-Gal4/+; UAS-i(CTG) 480 /+) originates a female-specific, semilethal phenotype at pupal stage 23 . To screen for molecules that suppressed that phenotype, we used a positional scanning synthetic combinatorial library (PS-SCL) of D-amino acid hexapeptides 24, 25 .
The library comprised 120 peptide mixtures, each of them containing approximately 2.5 million individual hexapeptides (19 5 ; D-Cys was omitted from the mixture positions). Each mixture addressed a separate, single position of the hexamer sequence. The 120 peptide mixtures were tested individually in vivo (80 µM) in nutritive media with 0.1% dimethyl sulfoxide (DMSO) 23 . The number of female flies that emerged was compared to DMSO-treated control individuals, and 28 peptide mixtures that significantly suppressed CUG-induced lethality were identified. Based on the screen results, 16 individual peptides were generated and evaluated (Supp. Table   S1 ). The hexapeptide Ac-ppyawe-NH 2 (ABP1; lower case one-letter code for D-amino acids) significantly suppressed lethality in a dose-dependent manner (Fig. 1A) . The individual contribution of each amino acid in ABP1 was determined using an alanine scanning, single substitution approach 26 .
Each mutant peptide (mut1 to mut5; see Supp. Table S1 ) was evaluated for its effect on the viability of 103Y-Gal4/+; UAS-i(CTG) 480 /+ female flies.
None of these peptides suppressed CUG-induced lethality, indicating that all amino acids in the original ABP1 sequence were necessary for its activity (Fig. 1B) . To examine whether ABP1 could non-specifically reduce UASi(CTG) 480 transcription, we measured luciferase reporter activity in flies of the genotype Myosin heavy chain (MHC)-Gal4/+; UAS-luciferase/+ after treatment with DMSO or ABP1. The results revealed no significant differences in the luciferase signal (Fig. 1C) . In addition, the levels of i(CUG) 480 transcripts in MHC-Gal4/+; UAS-i(CTG) 480 /+ flies were measured by semi-quantitative RT-PCR. We detected no reduction in the amount of toxic RNA in ABP1-treated individuals (Supp. Fig. S1A-B ).
To confirm that ABP1 could suppress CUG-induced toxicity in muscles, we analyzed ABP1 activity on a muscle degeneration phenotype caused by the expression of i(CUG) 480 in the indirect flight muscles (IFM) under the control of the MHC-Gal4 driver 23, 27 . ABP1 increased total muscle area in a dose-dependent manner up to 37.8% compared to DMSO-treated flies ( Fig. 1D-I ).
Transgenic expression of ABP1 in Drosophila suppressed CUGinduced phenotypes
In vivo ABP1 activity relied on its ability to diffuse through tissues and membranes, and to counteract CUG toxicity. To separate both properties, we performed tissue-specific expression of three transgenes that encoded ABP1-derivatives, UAS-ABP1f, UAS-ABP1r, and UAS-ABP1c. The UAS-ABP1f construct encoded a 10-mer peptide with a methionine and 
UAS-ABP1r
and UAS-ABP1c also suppressed muscle degeneration in the IFM, with a 3.5-fold increase in total muscle area (Supp. Fig. S2D-F ).
This effect was ~9 times stronger than that observed upon oral administration. Therefore, improving the bioavailability of the peptide enhanced its activity. In all cases, coexpression of UAS-i(CTG) 480 were detected between genotypes (Supp. Fig. S1C ).
ABP1 bound to CUG repeats in vitro without displacing Muscleblind
Binding of Muscleblind (Mbl) zinc finger domains to CUG repeats is strongly directed by the presence of aromatic residues 28 . The sequence of the ABP1 hexapeptide is also enriched in aromatic amino acids. We Fig. S4D ). These results suggested that ABP1 promoted a relaxation in the secondary structure of CUG60.
To confirm that ABP1 induced CUG-repeat RNA to change from a double-stranded to single-stranded conformation, we substituted a guanosine residue in a 23 CUG-repeat RNA with the adenosine analogue 2-amino purine (2AP-CUG23). The 2-amino purine fluorescence is strongly quenched in a base-paired structure, but it increases 2-3 fold in a singlestranded conformation 29 . When different concentrations of MblZF and ABP1
were incubated with the RNA at molar ratios lower than 1:5, neither the MblZF protein nor the ABP1 peptide disrupted the double-stranded RNA conformation (Supp. Fig. S4E ). However, at a molar ratio of 1:100 ABP1 caused a 2.9 fold increase in 2-AP fluorescence (Fig. 2F ). This indicated a switch from predominantly double-stranded to predominantly singlestranded conformation. In contrast, addition of DMSO alone, mut1 or mut4
did not modify 2AP-CUG23 fluorescence, demonstrating the specificity of the effect. Because double-stranded CUG and single-stranded CUG RNAs coexist in vitro, and Muscleblind proteins are known to bind CUG hairpins 3 , these results explained the additive behavior of ABP1 and MblZF observed in our polarization experiments.
ABP1 reduced CUG RNA foci formation and Muscleblind aggregation in Drosophila
In vitro results suggested that ABP1 activity relied on its ability to CUG expression caused Mbl to accumulate into nuclear aggregates (Fig.   3E ). However, ABP1 treatment induced a Muscleblind redistribution to a preferentially diffuse pattern, which also included the cytoplasm (Fig. 3F ).
ABP1 reversed missplicing and muscle histopathology in a DM1 mouse model
To confirm the effect of ABP1 in mammals, we used transgenic DM1 model mice that carry 250 (HSA .
Discussion
ABP1 efficiently suppressed CUG-induced phenotypes in three different
Drosophila tissues: brain, muscle, and eye. Moreover, the peptide significantly reduced the number of CUG RNA foci and caused a Mbl subcellular redistribution in the fly muscle. Two findings confirmed the specificity of ABP1 in vivo. First, ABP1 effects were dose-dependent in fly muscle, brain (oral administration), and eyes (transgenic expression).
Second, alanine-substituted peptide derivatives of ABP1 had no effect on CUG-induced lethality in flies. Thus, CUG toxicity was specifically suppressed by ABP1, and each amino acid in the peptide sequence was An important advantage of ABP1 is that it is composed of D-amino acids, which are not recognized by proteases. This, coupled with its small molecular weight (<900 Da), confers ABP1 with a potentially higher systemic bioavailability compared to larger L-amino acid peptides. The protease resistance of ABP1 also confers stability in the organism, and therefore it may exhibit long-lasting effects. This could account for our observation that the reversal of splicing defects and muscle histopathology in mice lasted for at least four weeks after one single injection. Based on our results, we propose that ABP1 represents a promising approach in the generation of new effective treatments for DM1. 
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